Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia.
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
W
W
Wang
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Z
Z
Chen
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Z
Z
Hu
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
C C
CC
Yin
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S
S
Li
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S
S
Bai
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
C E
CE
Bueso-Ramos
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
L J
LJ
Medeiros
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S
0000-0001-7110-3814
S
Hu
D000328:Adult; D000368:Aged; D002898:Chromosomes, Human, Pair 8 / Q000187:drug effects; D005260:Female; D006801:Humans; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D016019:Survival Analysis; D014314:Trisomy; D055815:Young Adult
D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases